Autologous T-cell vaccine - Opexa Therapeutics

Drug Profile

Autologous T-cell vaccine - Opexa Therapeutics

Latest Information Update: 17 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Institutes for Biological Sciences
  • Class
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 17 Sep 2009 Discontinued - Clinical-Phase-Unknown for Rheumatoid arthritis in China (SC)
  • 17 Sep 2009 Discontinued - Preclinical for Rheumatoid arthritis in USA (SC)
  • 08 Feb 2007 Interim results from a clinical trial in rheumatoid arthritis added to the Rheumatic Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top